TRAITEMENT DU CANCER À L'AIDE D'UNE COMBINAISON D'UN ANTAGONISTE DE PD-1 ET D'UN ANTAGONISTE D'IL-27

• 收藏
• 分享

专利权人:

Merck Sharp & Dohme Corp.

发明人:

SHIFRIN, Nataliya Tovbis,MALEFYT, Rene de Waal

申请号：

EP17862459

公开号：

EP3528834A4

申请日:

2017.10.19

申请国别(地区):

EP

年份:

2020

代理人:

摘要：

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an antagonist of IL-27, and the use of the combination therapies for the treatment of cancer. In certain embodiments, the PD-1 antagonist is an anti-human PD-1 antibody, or antigen binding fragment thereof. In further embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments the antagonist of IL-27 is an anti-IL-27 antibody, or antigen binding fragment thereof, an anti-p28 antibody, or antigen binding fragment thereof, or an anti-EBI-3 antibody, or antigen binding fragment thereof. Also provided are medicaments, compositions, and kits comprising a PD-1 antagonist and an IL-27 antagonist for use in treating cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/